索乐普尼(HMPL-523)治疗中国成人慢性原发性免疫性血小板减少症的有效性与安全性(ESLIM-01):一项随机、双盲、安慰剂对照的3期研究
ESLIM-01是在中国34个临床中心开展的随机、双盲、安慰剂对照3期试验,188例慢性原发性免疫性血小板减少症患者按2:1随机接受口服索乐普尼300 mg每日一次或安慰剂治疗24周。索乐普尼组持续缓解率为48%(61/126),安慰剂组为0(差值48%[95%CI 40-57];p<0.0001)。索乐普尼在中位8天起效,安全性总体可耐受,未发生死亡。
要点
- 索乐普尼组持续缓解率48%(61/126),安慰剂组为0,差值48%(95%CI 40-57;p<0.0001)。
- 索乐普尼组中位起效时间8天,安慰剂组为30天。
- 索乐普尼组3级及以上血小板计数降低发生率为7%(9/126),安慰剂组为10%(6/62)。
核心结论
- 索乐普尼在慢性原发性免疫性血小板减少症患者中显示出具有临床意义的持续血小板应答,安全性可耐受,并改善生活质量。
- 索乐普尼可能成为接受过一种或以上既往治疗的免疫性血小板减少症患者的潜在治疗选择。
研究设计与样本
- ESLIM-01是一项在中国34个临床中心开展的随机、双盲、安慰剂对照3期试验。
- 纳入18-75岁、ECOG体能状态0-1、接受过一种或以上既往治疗的慢性原发性免疫性血小板减少症患者。
- 患者按2:1随机接受口服索乐普尼或安慰剂300 mg每日一次,治疗24周。
- 随机分层因素为基线血小板计数、既往脾切除和基线时合并抗免疫性血小板减少症治疗。
- 共188例患者被随机分配至索乐普尼组(n=126)或安慰剂组(n=62)。
主要发现
- 主要终点达到:索乐普尼组持续缓解率为48%(61/126),安慰剂组为0,差值48%(95%CI 40-57;p<0.0001)。
- 索乐普尼组中位起效时间为8天,安慰剂组为30天。
- 索乐普尼组125例(99%)和安慰剂组53例(85%)报告治疗中出现的不良事件,大多数为轻或中度。
- 索乐普尼组与安慰剂组常见的3级及以上治疗中出现的不良事件:血小板计数降低7%(9/126)vs 10%(6/62),中性粒细胞计数降低3%(4/126)vs 0%(0/62),高血压3%(4/126)vs 0%(0/62)。
- 严重治疗中出现的不良事件发生率:索乐普尼组21%(26/126),安慰剂组18%(11/62);研究期间无死亡。
关键数值与推荐
- 主要终点为持续缓解率,定义为第14至24周六次计划访视中至少四次血小板计数≥50×10^9/L且不受挽救治疗影响,按意向治疗分析。
- 索乐普尼组持续缓解率48%(61/126)vs 安慰剂组0,差值48%(95%CI 40-57;p<0.0001)。
- 索乐普尼组中位起效时间8天 vs 安慰剂组30天。
- 索乐普尼组严重治疗中出现的不良事件21%(26/126)vs 安慰剂组18%(11/62)。
临床怎么用
- 索乐普尼可能成为接受过一种或以上既往治疗的免疫性血小板减少症患者的潜在治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, showed promising safety and activity in patients with primary immune thrombocytopenia in a phase 1b/2 trial. We aimed to evaluate the efficacy and safety of sovleplenib in patients with chronic primary immune thrombocytopenia. METHODS: This randomised, double-blind, placebo-controlled, phase 3 trial (ESLIM-01) was done in 34 clinical centres in China. Eligible patients, aged 18-75 years, had chronic primary immune thrombocytopenia, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and received one or more previous treatments. Patients were randomly assigned (2:1) to receive oral sovleplenib or placebo, 300 mg once daily, for 24 weeks. Randomisation was stratified by baseline platelet counts, previous splenectomy, and concomitant treatment for anti-immune thrombocytopenia at baseline. The primary endpoint was durable response rate (proportion of patients with a platelet count of ≥50 × 109/L on at least four of six scheduled visits between weeks 14 and 24, not affected by rescue treatment) assessed by intention-to-treat. The trial is registered with ClinicalTrials.gov, NCT05029635, and the extension, open-label phase is ongoing. FINDINGS: Between Sept 29, 2021, and Dec 31, 2022, 188 patients were randomly assigned to receive sovleplenib (n=126) or placebo (n=62). 124 (66%) were female, 64 (34%) were male, and all were of Asian ethnicity. Median previous lines of immune thrombocytopenia therapy were 4·0, and 134 (71%) of 188 patients had received previous thrombopoietin or thrombopoietin receptor agonist. The primary endpoint was met; durable response rate was 48% (61/126) with sovleplenib compared with zero with placebo (difference 48% [95% CI 40-57]; p<0·0001). The median time to response was 8 days with sovleplenib compared with 30 days with placebo. 125 (99%) of 126 patients in the sovleplenib group and 53 (85%) of 62 in the placebo group reported treatment-emergent adverse events (TEAEs), and most events were mild or moderate. Frequent TEAEs of grade 3 or higher for sovleplenib versus placebo were platelet count decreased (7% [9/126] vs 10% [6/62]), neutrophil count decreased (3% [4/126] vs 0% [0/62]), and hypertension (3% [4/126] vs 0% [0/62]). Incidences of serious TEAEs were 21% (26/126) in the sovleplenib group and 18% (11/62) in the placebo group. There were no deaths in the study. INTERPRETATION: Sovleplenib showed a clinically meaningful sustained platelet response in patients with chronic primary immune thrombocytopenia, with a tolerable safety profile and improvement in quality of life. Sovleplenib could be a potential treatment option for patients with immune thrombocytopenia who received one or more previous therapy. FUNDING: HUTCHMED and Science and Technology Commission of Shanghai Municipality.
引用
- Hu Y, Liu X, Zhou H, et al. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024. PMID: 38885672. doi:10.1016/S2352-3026(24)00139-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。